Michael Jorrin, "Doc Gumshoe"

Author Bio

Michael Jorrin,
I have been a medical writer for about 25 years; before that I was a documentary film maker, and some of my films were about medical subjects. I am not a physician, but I have a pretty good scientific background. I wouldn’t dream of recommending any kind of treatment to anyone, and I cannot give medical advice. However, I understand the medical literature and the data and evidence behind it, and I have an inquiring and skeptical turn of mind. I scrutinize and question and, sometimes, challenge the positions of some of the established health-care organizations as well as the marketers of health information. Eternal vigilance is a small price to pay for health. — Michael Jorrin (aka DocGumshoe) Michael Jorrin is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • The Miracle Cures Keep Coming 

    [ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

  • End of Winter Miscellany

    [ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]

  • Responses to Recent Comments

    [ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

  • Thanksgiving Leftovers and Short Takes

    [ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

  • Supplements and Drugs: the Feud Redux

    [ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

  • Yet More Miracle Cures From On High

    [ed note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us about health and medicine topics a couple times a month. He chooses his own topics, and his words and opinions are his own.] Travis lofted a couple of these over my transom […]

  • Two Flubs and a Big Question Mark

    [ed. note: Michael Jorrin, who I call “Doc Gumshoe,” writes for us a couple times a month on health and medical issues — he is a longtime medical writer (not a doctor), he chooses his own topics, and his past articles can be found here.] Flub Number One is the puncture of the “female Viagra” […]

  • What Do We Need to Know about Viruses?

    [ed. note: Michael Jorrin is a longtime medical writer (not a doctor), I’ve dubbed him “Doc Gumshoe” for his coverage of medical and health topics for Stock Gumshoe. This piece, like most of Michael’s work, is not specifically investment-related — but for those who think about speculating in the next Zika cure or similar “hot […]

  • Diets and Metabolic Tinkering

    [ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month. Like all of our authors, he chooses his own topics and his words and opinions are his alone. Enjoy!] While working […]

  • Recent Author Comments

    On End of Winter Miscellany
    Metformin's potential for increasing life-span was discussed at considerable length in a Doc Gumshoe piece on aging back in August 2015. The short take is that a cohort of people with diabetes treated with metformin had lower over-all mortality rates tha[...]
    On End of Winter Miscellany
    As in "The devil may care, but I don't care." My OED says, "The exclamation 'devil may care" used as an attribute: wildly reckless, careless and rolicking." A citation from Dickens, Pickwick Papers (1837): "He was a mighty free-and-easy, roving, devil-[...]
    On End of Winter Miscellany
    Controlling T2DM by means of diet and exercise may work for some individuals. I have a good friend whose T2DM was well-controlled by those means for several years, but eventually his A1c started to rise again and he had to resort to drug treatment. Mor[...]
    On Mampilly's "Untapped Ocean of Energy Found Under All 50 States"
    Here's to ten times ten more Gumshoe years! And that goes for Jen and the Gummie Sneakers as well![...]
    On Lichtenfeld's Alzheimer's Disease "Genius Molecule Discovery"
    AbbVie is an excellent, well-managed company with first-class research capabilities. I wouldn't dream of saying anything negative about an investment in their stock; over time AbbVie will surely do well since they have several current drugs that are effe[...]
    On Is Inflammation Really the Archvillain?
    Don't know much about anatabine, other than what I've learned on-line which you likely know already. A study that reported benefit consisted of an on-line survey of a couple of hundred people who were already anatabine users; most said it helped. Compa[...]
    On Is Inflammation Really the Archvillain?
    If using Voltaren or some other topical analgesic means you can reduce or omit the oral NSAID, that would "mitigate" the impact. But it depends on what you're treating. If you have RA, quelling the symptom does not stop the progress of the disease, whi[...]
    On Responses to Recent Comments
    From your comments I have gleaned sixteen different topics./ questions that I will look into in an upcoming post. I probably won't get to more than four or fine in any single post, because there are no quick and easy answers. But for now I need to resp[...]
    On Responses to Recent Comments
    I've been in Maine the past several days and have only now been able to read the comments. I will add some of your questions & comments to my "unfinished business:" list, which already had about half a dozen items that I hadn't addressed. Thank you[...]
    On Thanksgiving Leftovers and Short Takes
    Yes indeed, I try to base my conclusions on well-conducted research, and turn a skeptical eye on unsubstantiated claims. For example, I have written about telomeres in previous posts. I too would like longer telomeres, and there is pretty good evidence[...]
    On Thanksgiving Leftovers and Short Takes
    I meant for my comment above to be a reply to Ray's comment, sorry![...]
    On Thanksgiving Leftovers and Short Takes
    That must have been more than ten years ago! Niacin (Vitamin B3) does indeed increase HDL cholesterol and lower triglycerides, but has a smaller effect on LDL cholesterol. It tends to increase blood glucose levels, so may pose a risk of developing type[...]
    On A Defense against the Evil Cardiac Killer?
    My criticism of Dr Bereliani is based not just on the dubious merit of his supplement, but on his more basic disregard of medical interventions for cardiovascular disease that are supported by solid data. Steering patients away from treatment that works [...]
    On Skousen's "must have" cancer killer stock... and it's "one of the world's oldest, publicly traded companies"
    Agree with Travis, not surprisingly. Keytruda is a sound drug & can prolong the lives of patients with non-small cell lung cancers for maybe a year at most. Cimavax (the Cuban immunotherapy drug) is sometimes given with Keytruda. The hopes are th[...]
    On Such A Pleasant Stay
    I was very hot on Novo a couple of years ago, mostly because of their dominance in diabetes, but I never took the plunge. As for Celgene and also Gilead, we are now out, although perhaps not permanently.[...]
    On Robinson's "Most Lucrative New Investments" Pitch
    Knee replacement is fairly straightforward surgery. The function of a MEMS device would probably be to get the prosthesis implanted into the two leg bones so that the upper and lower legs line up properly. The tricky part of the surgery is getting all [...]
    On Medical Error: How Serious Is the Threat, and What Can We Do About It?
    In fact, the checklists used by pilots were in part the source of Provonost's checklist plan at Johns Hopkins.[...]
    On Medical Error: How Serious Is the Threat, and What Can We Do About It?
    Yes, but losing the appendix, even if tied off or clamped, could nevertheless have dire consequences![...]
    On On Nov. 4: "Deadly Strain of Old Man's Friend" to bring riches for Ernie Tremblay's teased stock?
    Agree partly, especially re aminoglycosides. Macrolide ototoxicity is generally short term. Macrolides are considered first-line therapy for CAP, along with some beta-lactams. The comparator drug in the solithromycin trials was often moxifloxacin, a [...]
    On On Nov. 4: "Deadly Strain of Old Man's Friend" to bring riches for Ernie Tremblay's teased stock?
    Dave, I don't think there are any data as yet on solithromycin's effects on hearing. Those reports may take some time to trickle in. But if you should happen to contract pneumonia, you don't necessarily have to take a macrolide. The ciprofloxacin-rel[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.